Evidence map›Paper›PMID 42036610›Full record

ReviewAdvances in experimental medicine and biology2026

The Role of Whole Exome Sequencing in the Genetic Evaluation of the Infertile Man.

Ginevra Farnetani, Viola Bonini, Csilla Krausz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ginevra FarnetaniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Viola BoniniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.
Csilla KrauszDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy. csilla.krausz@unifi.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Male infertility is a complex and multifactorial condition affecting up to 12% of men worldwide, with genetic factors playing a key role in all etiological categories. Current routine genetic tests include karyotyping, Y chromosome microdeletion analysis, and targeted multigene panel sequencing in selected phenotypes, e.g., congenital hypogonadotropic hypogonadism. Following a complete diagnostic workup, including the above genetic tests, approximately 50% of cases remain idiopathic. The advent of Whole Exome Sequencing (WES), has significantly enhanced our ability to uncover novel monogenic causes of male infertility and to redefine the diagnostic evaluation of infertile men. This chapter explores the dual role of WES as both a diagnostic strategy and a discovery tool, with a focus on the implementation of WES-derived virtual gene panels (VGPs). These panels allow for dynamic, cost-effective reanalysis and are increasingly applied in clinical genetics. We discuss about gene-disease relationships (GDRs), highlight validated genes with diagnostic utility, and pinpoint emerging candidate genes across qualitative and quantitative spermatogenic disorders. Finally, we examine the clinical implications of genetic diagnosis, emphasizing the role of personalized genetic counseling in optimizing assisted reproductive outcomes and informing short- and long-term health risks for patients and their offspring.

Indexed as

ExomeExome SequencingGenetic TestingInfertility, MaleGenetic Predisposition to DiseaseHumansMaleAzoospermiaDiscoveryGene-disease relationshipGenetic diagnosisMale infertilityTeratozoospermiaVirtual gene panelWhole exome sequencing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.